摘要
目的 旨在研究血管紧张转换酶 (ACE)抑制剂培哚普利和血管紧张素Ⅱ受体的Ⅰ型受体 (AT1R)拮抗剂Irbesartan对循环和心脏局部组织肾素—血管紧张素系统 (RAS)影响。方法 采用大鼠腹主动脉缩窄模型 ,用放射免疫法测定血浆肾素 (RA)浓度、血管紧张素Ⅱ (AngⅡ )含量 ,心肌RA浓度、AngⅡ含量 ;比色法测血清和心肌ACE活性。结果 循环AngⅡ含量、ACE活性与LVMI之间均无相关性 (r1=0 .0 96 7,r2 =0 .145 0 ,P >0 .0 5 )。Irbestarsan组循环中RA、AngⅡ含量和ACE活性显著高于手术组 (P <0 .0 1) ;培哚普利组循环RA显著高于手术组 (P <0 .0 1) ,ACE活性和AngⅡ含量显著低于手术组 (P <0 .0 1)。手术组心肌AngⅡ含量、ACE活性均与LVMI呈显著正相关 (r1=0 .82 6 6 ,r2 =0 .82 8P <0 .0 1)。Irbesartan组心肌RA、AngⅡ和ACE均显著低于手术组 (P<0 .0 1) ;培哚普利组心肌RA显著高于手术组 (P<0 .0 5 ) ,但ACE活性和AngⅡ含量显著低于手术组 (P<0 .0 1)。结论 心脏局部组织RAS而非循环RAS在压力超负荷致心肌肥大中起重要作用 ,培哚普利和Irbesartan防止心肌肥厚发生的重要机制之一是阻断心脏组织RAS ,抑制心肌组织局部AngⅡ的生成。
Aim:To investigate the effects of Irbesartan and peridopril on circulating and local renin-angiiotension system (RAS)in rats.Methods:Male wistar rats were divided randomly into 4 group:shame-operated(So), abdominal aorta constriction(AC), AC with Irbesartan(AC+Irb),AC with Peridopril(AC+Per). At 10th week after operation,circulating and ventricular renin activity (RA),angiotensin Ⅱ(Ang Ⅱ),angiotensin I converting enzyme(ACE) activity were measured respectively by radioimmunoassay(RIA) and biochemical analysis.Results:Levels of circulating RA,Ang Ⅱ and ACE in AC+Irb were significantly higher than those in AC (P<0.01),Plasma RA in AC+Per was significantly higher than that in AC(P<0.01),plasma Ang Ⅱ and serum ACE were significantly lower than those in AC(0.01).Components of cardiac RAS in AC+Irb were significantly lower than those in AC(P<0.05). Compared with AC, ventricular RA in AC+Per was decreased obviously (P<0.01),ACE and Ang Ⅱ were increased obviously(P<0.01).Left ventricular mass index(LVMI) was positivily correlated with both ventricular ACE and Ang Ⅱ(r 1=0.8266,r 2=0.828 P<0.01),not with circulating ACE and Ang Ⅱ. Conclusion:These results suggest that cardiac RAS plays an important role in the cardiac hypertrophy during pressure over-loading.A machanism of preventing cardiac hypertrophy by Irbesartan and Peridopril is due to blocking cardiac RAS, inhibiting production of ventricular Ang Ⅱ.
出处
《重庆医学》
CAS
CSCD
2000年第4期306-307,共2页
Chongqing medicine
